Smart Integrated Biodiagnostic Systems for Healthcare

The SmartHEALTH project is designed to develop and deliver the next generation of smart bio-diagnostic systems capable of being fully integrated into healthcare systems in Europe. Driven by key applications in cancer diagnostics, SmartHEALTH will enable enhanced medical diagnosis leading to earlier and more precise results and thus contributing to an increased quality of life.

In addressing the high economic burden of the healthcare sector, prevention, early diagnosis and informed therapeutics are indispensable. Tests must be highly accurate and well integrated into medical management to avoid unnecessary treatment and stress to users.

SmartHEALTH will address these complex issues by developing highly intelligent diagnostic technologies that can be fully integrated into healthcare systems, optimising their impact in management and work practice. Driven by key targeted applications in cancer diagnostics (breast, cervical and colorectal), the project will deliver prototype systems with the aim of moving instrumentation from the laboratory, through to portable devices localised at the "point of care".

Cancers are not 'cured' but 'managed'. One of the major areas of progress with cancers, for example, breast cancer, is the benefit of long term therapies for reducing growth rates. This approach requires regular monitoring such that the efficacy of maintenance therapy is rapidly noted and different therapy can be initiated if and when required. This necessitates regular testing for cancer load. People wish to avoid hospital yet want results interpreted expertly and communicated rapidly. They want tests that do not miss problems yet avoid unnecessary worry. SmartHEALTH aims to develop such integrated cancer monitoring diagnostic devices, eventually useable in localized and more available settings.

The overall SmartHEALTH objectives include:

  • Introduce new SmartHEALTH sensor systems into future healthcare services to improve and better existing services
  • Demonstrate the role of on-line services for pervasive healthcare provision
  • Demonstrate clinical evaluation of systems for targeted applications in breast, cervical and colorectal cancer
  • Assess the economic benefits and means of healthcare provision for the targeted clinical applications
  • Develop new manufacturing and packaging technologies for realisation of unique sensor solutions integrating fluidics, transducers and biological assays
  • Facilitate ethical and social acceptance of SmartHEALTH technology

The SmartHEALTH project will be present at booth F29/2 at ComPaMed, Düsseldorf/Germany, to display a desktop POC instrument for detection of cancer markers, a series of detection chips (Electrochemical Detection Chip, Circular Disc Resonator Sensor, qPCR chip for detection of HPV, qPCR chip for detection of colorectal cancer, and a number of fluidic modules such as RNA-extraction, plasma generation, lyophilisation platforms, or micro mixers.

The project is also organising a workshop on Friday, 20th November, 11:00-13:30, within the ComPaMed Forum which includes a Panel Discussion on "Enabling Point-of-Care Diagnostics: Lab-on-a-Chip innovative Sensor Technologies".

For further information, please visit:
http://www.smarthealthip.com

Related article:

About the SmartHEALTH Integrated Project
Driven by clinical applications and MNT & IST technology, the SmartHEALTH project will develop an open integrated architecture for new biodiagnostic systems to support European companies exploiting bioassays or new application concepts. The initial system has a disposable fluidic cartridge with a desktop base-station linking to the ambient e-Health environment. Ultimately, this system will perform multi-analyte sensing and data/trend analysis for nucleic acids and proteins and will be modular to allow multiple biological sample types to be dealt with. Results will be interpreted and presented using bio-information analysis based on trained neural networks. Systems will be healthcare "user identity-" and "ambient environment-" aware, respecting confidentiality and information access rights. This concept will be miniaturized and cost engineered into a portable and more available system. The project will enable enhanced medical diagnosis, leading to earlier and more precise results contributing to an increased quality of life as well as increasing the competitiveness of the European in vitro diagnostics (IVD) sector. Clinical areas for SmartHEALTH application are in Cancer Diagnostics - breast cancer recurrence monitoring, cervical cancer case finding, and colorectal cancer diagnostics, prognostics and theranostics. Each application includes clinical instrument evaluation and commercial exploitation partners.

The SmartHEALTH Integrated Project is funded by the European Commission under project identifier FP6-2004-IST-NMP-2-016817.

Most Popular Now

Herefordshire and Worcestershire Health …

Herefordshire and Worcestershire Health and Care NHS Trust has successfully implemented Alcidion's Miya Precision platform to streamline bed management workflow across seven community hospitals in Worcestershire. The trust delivers community...

A Shortcut for Drug Discovery

For most human proteins, there are no small molecules known to bind them chemically (so called "ligands"). Ligands frequently represent important starting points for drug development but this knowledge gap...

New Horizon Europe Funding Boosts Europe…

The European Commission has announced the launch of new Horizon Europe calls, with a substantial funding pool of over €112 million. These calls are aimed primarily at pioneering projects in...

Cleveland Clinic Study Finds AI can Deve…

Cleveland Clinic researchers developed an artficial intelligence (AI) model that can determine the best combination and timeline to use when prescribing drugs to treat a bacterial infection, based solely on...

New AI-Technology Estimates Brain Age Us…

As people age, their brains do, too. But if a brain ages prematurely, there is potential for age-related diseases such as mild-cognitive impairment, dementia, or Parkinson's disease. If "brain age...

With Huge Patient Dataset, AI Accurately…

Scientists have designed a new artificial intelligence (AI) model that emulates randomized clinical trials at determining the treatment options most effective at preventing stroke in people with heart disease. The model...

Radboud University Medical Center and Ph…

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Radboud University Medical Center have signed a hospital-wide, long-term strategic partnership that delivers the latest patient monitoring...

GPT-4, Google Gemini Fall Short in Breas…

Use of publicly available large language models (LLMs) resulted in changes in breast imaging reports classification that could have a negative effect on patient management, according to a new international...

ChatGPT fails at heart risk assessment

Despite ChatGPT's reported ability to pass medical exams, new research indicates it would be unwise to rely on it for some health assessments, such as whether a patient with chest...

Study Shows ChatGPT Failed when Challeng…

With artificial intelligence (AI) poised to become a fundamental part of clinical research and decision making, many still question the accuracy of ChatGPT, a sophisticated AI language model, to support...

Virtual Reality Shows Promise in Fightin…

A new study published in JMIR Mental Health sheds light on the promising role of virtual reality (VR) in treating major depressive disorder (MDD). Titled "Examining the Efficacy of Extended...

AXREM and Highland Marketing Partner to …

AXREM represents member companies that collectively provide UK hospitals with most of their diagnostic medical imaging technology, and radiotherapy equipment. The association has seen substantial growth in recent years, with membership...